RxDoctor Payments Data

Alyssa Vidal

Nurse Practitioner · Hemet, CANPI 1245706605

Payments from drug & device makers

$1,962in general payments, 2019–2025

Across 73 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$647
  • Akebia Therapeutics Inc$391
  • AstraZeneca$323
  • Amgen$249
  • Vifor Pharma, Inc.$143
  • Novo Nordisk$85
  • plus $124 from 4 others

What the payments were for

  • Food & beverage$1,92998%
  • Education$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,962 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$23,838
Medicare patients
62
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide44$106,378
XphozahTenapanor Hcl39$105,052
AuryxiaFerric Citrate63$95,763
LokelmaSodium Zirconium Cyclosilicate43$30,701
Sevelamer Carbonate151$29,047
VeltassaPatiromer Calcium Sorbitex23$27,541
Sevelamer Hcl13$24,087
ProsolParenteral Amino Acid 20% No.1170$23,590
Calcium Acetate97$12,001
Nifedipine ErNifedipine79$3,016
Ondansetron OdtOndansetron58$1,421
Megestrol Acetate21$1,381
Midodrine Hcl43$663
Hydralazine Hcl52$580
Lidocaine-PrilocaineLidocaine/Prilocaine24$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$58$106,37844 claims
Akebia Therapeutics IncAuryxia$391$95,76363 claims
AstraZenecaLokelma$323$30,70143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →